The GLP-1 Coverage Reckoning Is Reaching U.S. Employers

For U.S. employers, the question surrounding GLP-1 drugs is becoming less about whether the medicines work and more about who should pay for them. As healthcare budgets come under renewed pressure, companies that once viewed weight-loss drugs as an attractive employee benefit are reassessing whether they can continue to cover them at their current cost.

The shift could become more visible in 2027. A Business Group on Health survey found that 67% of its surveyed employers covered GLP-1 medicines for weight management in 2026. Among those employers, only 72% said they were likely to continue that coverage in 2027, while 10% said they likely would not. Reuters, citing the same survey, reported that about 14% of employers had already dropped or planned to drop such coverage.

The distinction matters because GLP-1 drugs are not being rejected as ineffective. Rather, employers are confronting a difficult economic calculation: how much should a company spend today on a treatment whose potential savings may arrive years later, and may not necessarily accrue to the same employer or insurer?

A benefit caught between promise and price

GLP-1 medicines, including Novo Nordisk's Wegovy and Eli Lilly's Zepbound, were initially developed primarily around diabetes treatment but have become increasingly important in obesity management. Their ability to produce substantial weight loss has expanded the potential market well beyond traditional diabetes care.

For employers, that creates both an opportunity and a liability. Better management of obesity could theoretically reduce the incidence or severity of related conditions and improve employees' health over time. But those potential benefits must be weighed against immediate pharmacy spending.

Business Group on Health found that nearly eight in 10 surveyed employers reported that GLP-1s were increasing their healthcare costs. More than half of employers covering the drugs for weight management expected significant clinical benefits, yet few had already seen corresponding evidence in their aggregate claims data, such as lower obesity rates or fewer employees requiring bariatric surgery.

That gap between expected long-term benefits and measurable short-term savings is central to the coverage debate.

The wider healthcare squeeze

GLP-1s are arriving at a particularly difficult moment for corporate health plans. Aon projects that U.S. employer healthcare costs will rise 9.5% in 2027, taking average costs above $19,000 per employee. It would be the fourth consecutive year of near-double-digit growth. Aon attributes the increase to greater use of healthcare services, chronic conditions, high-cost claims and rising prescription-drug spending, including specialty medicines and GLP-1 therapies.

That broader pressure changes the economics of every benefit decision. A company that might previously have tolerated rapid growth in one category can become less willing to do so when hospital, physician and pharmacy costs are rising simultaneously.

Employers are therefore not necessarily choosing between GLP-1 coverage and no coverage. Many are moving toward tighter management. Business Group on Health reports that companies use measures such as clinical eligibility requirements, weight-management programs, limits on prescribing providers and formulary restrictions to control utilization.

Mercer has similarly reported that some large employers are dropping coverage, while others are tightening utilization controls or reconsidering their relationships with pharmacy-benefit managers.

Why oral drugs could complicate the calculation

The next phase of the GLP-1 market could make the employer decision harder rather than easier.

Business Group on Health found that 87% of surveyed employers expected the arrival of oral GLP-1 medicines to increase overall demand, while only 9% expected prices to decline. If easier administration expands the pool of potential users without producing comparable reductions in treatment costs, employers could face another increase in pharmacy spending.

At the same time, greater competition could eventually change pricing dynamics. New products, different formulations and additional manufacturers may create negotiating leverage for employers and insurers. But that outcome remains uncertain, and companies planning their 2027 benefits cannot rely on future competition alone to resolve current budget pressures.

The cost can move to workers

When employers reduce coverage, the financial effect does not disappear. It can shift to employees, insurers or pharmaceutical companies, depending on how a plan is structured.

A worker whose employer excludes weight-loss treatment may have to pay directly, use another source of coverage or forgo treatment. Higher employee costs can make a benefits package less attractive, particularly for workers who place significant value on comprehensive healthcare coverage.

Employers therefore face a compensation trade-off. Absorbing rising pharmacy costs protects employees but raises total labor costs. Shifting more costs to workers protects corporate budgets but can reduce the perceived value of employment and increase household financial pressure.

Mercer reports that employers are also considering broader changes to medical plans that could increase employee out-of-pocket costs as healthcare inflation persists.

The business case remains unresolved

For investors and corporate executives, the most important issue may be whether GLP-1 spending eventually produces measurable economic returns.

If treatment reduces costly complications, improves health outcomes or lowers other medical spending, continued coverage could become easier to justify. If those savings remain difficult to demonstrate within an employer's claims data, companies may increasingly view weight-management GLP-1s as an expensive benefit rather than a cost-saving healthcare intervention.

There is also a timing problem. Employees change jobs, insurers change and treatment can continue for years. A company paying for medication today may not capture the full financial benefit of improved health in the future. That weakens the incentive for employers to make large upfront investments even if the treatment could be beneficial over a longer horizon.

The result is likely to be a more selective market rather than a simple retreat. Some employers may continue broad coverage, while others impose stricter eligibility rules, negotiate different pharmacy arrangements or exclude weight-management indications while maintaining coverage for diabetes and other approved uses.

What happens next

The direction of employer coverage will depend on several variables: drug prices and rebates, competition among manufacturers, the availability of oral formulations, clinical evidence, employee demand and the broader trajectory of healthcare costs.

The International Foundation of Employee Benefit Plans found in its 2026 survey that 36% of corporate employers covered GLP-1 drugs for both diabetes and weight loss, while 60% covered them for diabetes only. The findings underscore how differently employers are already approaching the same class of medicines.

For pharmaceutical companies, that makes employer formularies an important commercial battleground. For employers, it makes GLP-1 coverage part of a much larger question about how healthcare benefits should be financed.

The emerging debate is therefore not simply about weight-loss drugs. It reflects a broader tension in the U.S. healthcare system: when a treatment is expensive today but may produce benefits tomorrow, deciding who should bear the cost becomes as important as deciding whether the treatment works.